Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine

Gajanan Sapkal; Pragya D Yadav; Raches Ella; Priya Abraham; Deepak Y Patil; Nivedita Gupta; Samiran Panda; V Krishna Mohan; Balram Bhargava

doi:10.1093/jtm/taab077

Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine

J Travel Med. 2021 Oct 11;28(7):taab077. doi: 10.1093/jtm/taab077.

Authors

Gajanan Sapkal¹, Pragya D Yadav¹, Raches Ella², Priya Abraham¹, Deepak Y Patil¹, Nivedita Gupta³, Samiran Panda³, V Krishna Mohan², Balram Bhargava³

Affiliations

¹ Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.
² Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India.
³ Indian Council of Medical Research, New Delhi, India.

Abstract

Our study has shown 1.09 and 1.92 fold reductions in the neutralizing titer with sera of individuals with natural infection and Covaxin vaccine recipients against B.1.1.28.2 variant.

Keywords: B.1.1.28.2; Covaxin; SARS-COV-2; neutralization; vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
COVID-19 Vaccines*
COVID-19*
Humans
Neutralization Tests
SARS-CoV-2

Substances

Antibodies, Neutralizing
COVID-19 Vaccines

Grants and funding

Indian Council of Medical Research